The APOC1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 human lung adenocarcinoma epithelial cells, designed to disrupt the APOC1 gene. This polyclonal pool contains a heterogeneous mix of gene-edited cells, enabling robust population-level loss-of-function studies while avoiding clonal bias.
The A-549 cell line was isolated from a 58-year-old Caucasian male with lung adenocarcinoma and serves as a well-established model of alveolar Type II epithelial cells. It is extensively used in cancer research for studying tumorigenesis, drug metabolism, and resistance mechanisms, and retains key epithelial characteristics relevant to pulmonary biology.
APOC1 encodes apolipoprotein C-I, a component of VLDL, HDL, and chylomicrons that inhibits lipoprotein lipase (LPL) and hepatic lipoprotein uptake mediated by LRP1 and the VLDL receptor, thereby elevating plasma triglycerides. It also activates LCAT, promoting cholesterol esterification and HDL remodeling. APOC1 transcription is induced by LXR, PPAR??, PPAR??, and RXR in response to insulin and dietary fatty acids, integrating metabolic and inflammatory signals. APOC1 interacts with APOE on lipoproteins and regulates monocyte adhesion, linking lipid transport to vascular inflammation.
In A-549 lung adenocarcinoma cells, APOC1 knockout is expected to perturb lipid homeostasis, potentially altering lipid raft composition and downstream oncogenic signaling. This disruption may affect cell proliferation, migration, and chemosensitivity, given the importance of lipid metabolism in supporting tumor growth. The knockout model allows exploration of whether APOC1 modulates LCAT activity and triglyceride clearance in the tumor microenvironment, and whether it influences immune cell interactions through monocyte adhesion pathways.
This knockout cell population is suited for investigating APOC1 function in lipid metabolism and lung adenocarcinoma, including drug metabolism and resistance studies. Standard assays include RT-qPCR and Western blotting for knockout verification, lipid uptake and metabolism assays, cell proliferation and migration screens, RNA-seq for transcriptomic profiling, and LCAT activity and triglyceride quantification. It also supports high-throughput screening of compounds targeting lipid-related oncogenic pathways. For further information, contact Ascent Research.
